- Volume is elevated versus the 13-week average, confirming attention.
- Latest weekly return ranks in the strongest part of its sector group.
PHARM
AMS
Week ended 07 Aug 2026
Weekly Investor Report
Pharming Group N.V. · Healthcare · Biotechnology
Latest close
0.95 EUR
10.0%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -25.9% below the Trend Line and sits at 12.2% of its 52-week range. The latest completed week returned 10.0%, after a -20.6% four-week move. The latest news-sentiment score is 43/100.
Setup score
29
out of 100
Latest Close
0.95 EUR
7 Aug 2026
1W Return
10.0%
latest completed week
4W Return
-20.6%
short-term follow-through
12W Return
-14.0%
quarterly tape
Trend Breadth
65.4%
34 of 52 weeks active
Volume Ratio
2.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
10.0%
Latest completed week; four-week move -20.6%.
Indicator stack
36/30
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
43/100
2 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -25.9% below the Trend Line and sits at 12.2% of its 52-week range. The latest completed week returned 10.0%, after a -20.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.1x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0312-week average 0.16
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -20.6% over four weeks, -14.0% over 12 weeks, and -6.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year34
Trend breadth65.4%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.14Latest activity-pressure read.
Pressure change2.8%Four-week change in activity pressure.
Leadership-34.76Latest relative-leadership reading.
RS change-113.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment43/100
Weighted news tone is neutral across 2 relevant articles.
1 positive · 0 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-47.5%Distance below the 52-week high.
13-week volatility7.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher14 of 2612 weeks finished lower.
Best week+10.0%Week of 7 Aug.
Worst week-23.0%Week of 8 May.
Latest week+10.0%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains9
Flat weeks0
Modest losses7
Sharp losses5
Recent vol7.0%13-week weekly-return volatility.
Base vol8.3%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew5.4% / -5.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorNL Healthcare
4-week rank3 / 3
Group average-12.9%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD66.7%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
IndustryNL Biotechnology
4-week rank2 / 2
Group average-17.5%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD50.0%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape32/100
Trend, activity pressure, participation, and risk combine to a 32/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.03; No reversal markers Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment43/100Weighted news tone is neutral across 2 relevant articles.
Pharming Group N.V. Stock 12‑Month Price Target Cut to $30.37, Implies 153% Upside Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 0.95 EUR | 10.0% | 1.29 EUR | 1.04 EUR | -1.14 | -34.76 | 76.9M | Off |
| 31 Jul 2026 | 0.87 EUR | -21.3% | 1.31 EUR | 1.04 EUR | -1.06 | -40.30 | 115.5M | Off |
| 24 Jul 2026 | 1.10 EUR | -3.8% | 1.33 EUR | 1.04 EUR | -1.01 | -23.79 | 23.9M | Off |
| 17 Jul 2026 | 1.15 EUR | -4.7% | 1.34 EUR | 1.04 EUR | -1.09 | -20.81 | 31.1M | Off |
| 10 Jul 2026 | 1.20 EUR | -2.1% | 1.35 EUR | 1.04 EUR | -1.17 | -16.25 | 43.5M | Off |
| 3 Jul 2026 | 1.23 EUR | 5.3% | 1.36 EUR | 1.04 EUR | -1.38 | -14.18 | 10.1M | Off |
| 26 Jun 2026 | 1.17 EUR | 3.2% | 1.36 EUR | 1.04 EUR | -1.54 | -16.57 | 8.7M | Off |
| 19 Jun 2026 | 1.13 EUR | 1.4% | 1.37 EUR | 1.04 EUR | -1.55 | -20.35 | 4.3M | Off |
| 12 Jun 2026 | 1.11 EUR | -0.3% | 1.38 EUR | 1.04 EUR | -1.63 | -21.61 | 5.9M | Off |
| 5 Jun 2026 | 1.12 EUR | -3.0% | 1.39 EUR | 1.04 EUR | -1.66 | -18.40 | 18.2M | Off |
| 29 May 2026 | 1.15 EUR | 3.0% | 1.40 EUR | 1.04 EUR | -1.58 | -15.47 | 64.0M | Off |
| 22 May 2026 | 1.12 EUR | 0.8% | 1.40 EUR | 1.04 EUR | -1.44 | -18.67 | 31.0M | Off |
| 15 May 2026 | 1.11 EUR | 0.5% | 1.41 EUR | 1.04 EUR | -1.23 | -16.49 | 50.7M | Off |
| 8 May 2026 | 1.10 EUR | -23.0% | 1.41 EUR | 1.04 EUR | -0.92 | -17.30 | 143.5M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.